Results 181 to 190 of about 29,283 (270)

Delayed Occurrence of Lung Cancer Leptomeningeal Metastasis and Era‐Associated Post‐LM Survival: A 14‐Year Single‐Center Cohort Study

Thoracic Cancer, Volume 17, Issue 17, September 2026.
In 201 cytology‐confirmed lung cancer LM cases, the modern era was associated with later LM diagnosis but no significant unadjusted improvement in post‐LM survival. Paired tissue‐CSF profiling identified actionable driver discordance in 8.75%, supporting CSF testing and improved CNS‐penetrant, molecularly matched therapies.
Xiaoxing Gao, Jie Gao, Qiuyue Ye, Chen Wei, Qing Zhou, Xiaoyan Liu, Minjiang Chen, Jing Zhao, Hanping Wang, Xiaoyan Si, Wei Zhong, Yan Xu, Mengzhao Wang   +12 more
wiley   +1 more source

Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Wang Y, Wu S, Wei Y, Fan S, Xu Z, Li D, Teng Z, Wang J.   +7 more
europepmc   +1 more source

Low Torque Teno Virus Load Is Associated With Fibrosis in Protocol Biopsies Following Liver Transplantation: A Nordic Multicenter Cohort Study

APMIS, Volume 134, Issue 9, September 2026.
ABSTRACT Graft inflammation and fibrosis are associated with progressive fibrosis and potential graft loss after liver transplantation, but diagnosis relies on invasive biopsies. Torque teno virus (TTV) may be a noninvasive marker of functional immunity, however its association with these changes remains unclear. In this Nordic multicenter cohort study,
Delal Akdag, Jeanett Klubien, Andreas Arendtsen Rostved, Allan Rasmussen, Nikolai Kirkby, Gro Linno Willemoe, Deepthi Chiranth, Bo‐Göran Ericzon, Carl Jorns, William Bennet, Arno Nordin, Fredrik Åberg, Jens Georg Hillingsø, Susanne Dam Nielsen, Hans‐Christian Pommergaard   +14 more
wiley   +1 more source

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA Oncol
Tarantino P, Li T, Ogayo ER, Rahman T, DiLullo MK, Patel A, El-Refai S, Abbott C, Li B, Boyle SM, Chen RO, Desai NV, Spring LM, Tung NM, Sinclair N, Faggen M, Constantine M, King TA, Krop IE, Tayob N, Mittendorf EA, Tolaney SM, Winer EP, Parsons HA, Waks AG.   +24 more
europepmc   +1 more source

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non‐muscle‐invasive bladder cancer

BJU International, Volume 138, Issue 3, Page 491-500, September 2026.
Objectives To evaluate whether longitudinal tumour‐informed circulating tumour DNA (ctDNA) testing identifies patients at increased risk of upstaging and recurrence in high‐risk non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods A cohort of 52 patients with high‐risk NMIBC underwent serial plasma ctDNA testing using a personalised tumour ...
Can Aydogdu, Betty Wang, Sean Thomas McSweeney, Gabriela Diaz, Taeris Guzman, Sahab Ram Dewala, Rakesh Arya, Mikayla Baer, Amanda Nizam, Christopher Wee, Shalini Moningi, Alberto Pieretti, Christopher J. Weight, Rebecca Campbell, Mohit Sindhani, Jihad Kaouk, Robert Abouassaly, Laura Bukavina   +17 more
wiley   +1 more source

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial. [PDF]

ESMO Open
Blaye C, Bidard FC, Hue L, Howarth K, Pierga JY, Dalenc F, Jacot W, Djerroudi L, Potonnier W, Dumas V, Lalet C, Maréchal M, Pulido M, Brunet M, Salabert L, Venat L, Maran-Gonzalez A, Saal LH, Franchet C, Birkeälv S, MacGrogan G, Bonnefoi H.   +21 more
europepmc   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

Cancer Science, Volume 117, Issue 9, Page 2426-2442, September 2026.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Hisao Higo, Kammei Rai, Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Ryohei Katayama, Kadoaki Ohashi   +22 more
wiley   +1 more source

Association of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta-Analysis. [PDF]

CNS Neurosci Ther
Yang S, Zhang Z, Dong H, Yu X, Zhu F, Yang S.   +5 more
europepmc   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, Volume 37, Issue 5, Page 438-448, September 2026.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Dac DT, Tanaka H, Takami A, Espinoza JL.
europepmc   +1 more source